Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Cash Flows

v3.10.0.1
Condensed Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Operating activities    
Net loss $ (19,429) $ (19,131)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 727 414
Stock-based compensation 3,016 9,980
Unrealized transaction gain (loss) on related party activity 12 (8)
Changes in operating assets and liabilities:    
Trade accounts receivable   110
Due to/from related parties 576 1,534
Prepaid expenses and other assets (325) (260)
Accounts payable 217 205
Accrued salaries, wages, and other compensation 70 160
Accrued liabilities 1,770 1,250
Deferred revenue (234) (222)
Net cash used in operating activities (13,600) (5,968)
Investing activities    
Purchases of property and equipment, net (830) (1,614)
Net cash used in investing activities (830) (1,614)
Financing activities    
Advances from Cellectis   3,000
Repayment of advances from Cellectis   (3,000)
Costs incurred related to the issuance of stock (222) (3,330)
Proceeds from common stock issuance 57,706 61,292
Proceeds from the exercise of stock options 2,128 182
Financing lease obligation   6,957
Net cash provided by financing activities 59,612 65,101
Net increase in cash, cash equivalents and restricted cash 45,182 57,519
Cash, cash equivalents and restricted cash-beginning of period 56,664 5,026
Cash, cash equivalents and restricted cash-end of period 101,846 62,545
Supplemental cash flow information    
Interest paid 856 44
Supplemental non-cash investing and financing transactions:    
Property and equipment included in financing lease obligations 6,849  
Offering costs in accounts payable and accrued liabilities $ 443 $ 2,081